Immune checkpoint inhibitors (ICI) in clear cell renal cell carcinoma (ccRCC) following high-dose interleukin-2 (IL-2)

被引：0
|
作者：
Elias, Roy
Bowman, Isaac Alexander
Hammers, Hans J.
Brugarolas, James
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[2] Univ Texas Southwestern, Dallas, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
635
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical benefit (CB) of high-dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC)
    Agarwal, Neeraj
    Parikh, Kinjal
    Tantravahi, Srinivas Kiran
    Crispin, Hilda
    Van Atta, Joan
    Batten, Julia Anne
    Sageser, Daniel
    Samlowski, Wolfram E.
    Grossmann, Kenneth F.
    Wang, Junfeng
    Stenehjem, David D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [2] Phase II trial of high-dose interleukin-2 (IL-2) and stereotactic radiation therapy (SABR) for metastatic clear cell renal cell carcinoma (ccRCC): Interim analysis.
    Hannan, Raquibul
    Ishihara, Dan
    Louder, Kristi
    Ahn, Chul
    Margulis, Vitaly
    Arriaga, Yull Edwin
    Courtney, Kevin Dale
    Timmerman, Robert D.
    Brugarolas, James
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [3] Sequential Immune Monitoring of Melanoma and Renal Cell Carcinoma Patients Treated with High-dose Interleukin-2 (IL-2): Immune Patterns and Prognosis
    Foureau, D. M.
    Amin, A.
    Norton, H.
    Sarantou, T.
    McKillop, I. H.
    White, R. L.
    Salo, J. S.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S116 - S116
  • [4] High-dose interleukin-2 in metastatic renal cell carcinoma
    Fernández-Rodríguez, R
    de Argumedo, GL
    Mañé, JM
    Muñoz, A
    Ferreiro, J
    Fuente, N
    López-Vivanco, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) : 6797 - 6798
  • [5] Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).
    Clark, Joseph
    Morse, Michael A.
    Wong, Michael K. K.
    McDermott, David F.
    Kaufman, Howard
    Daniels, Gregory A.
    Perritt, Jessica C.
    Hua, Hong
    Aung, Sandra
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [6] The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma
    Hughes, Tasha
    Klairmont, Matthew
    Broucek, Joseph
    Iodice, Gail
    Basu, Sanjib
    Kaufman, Howard L.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (04) : 459 - 465
  • [7] The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma
    Tasha Hughes
    Matthew Klairmont
    Joseph Broucek
    Gail Iodice
    Sanjib Basu
    Howard L. Kaufman
    Cancer Immunology, Immunotherapy, 2015, 64 : 459 - 465
  • [8] The application of high-dose interleukin-2 for metastatic renal cell carcinoma
    McDermott, David F.
    MEDICAL ONCOLOGY, 2009, 26 : 13 - 17
  • [9] High-dose interleukin-2 in metastatic renal cell carcinoma - Reply
    McDermott, DF
    Atkins, MB
    Regan, MM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) : 6798 - 6799
  • [10] The application of high-dose interleukin-2 for metastatic renal cell carcinoma
    David F. McDermott
    Medical Oncology, 2009, 26 : 13 - 17
12345